Elite Journal of Health Sciences. Volume 2 issue 3(2024), Pp. 53-67
https://epjournals.com/journals/EJHS

Impaired Neutrophil Chemotaxis and HIV-Associated Diarrhea: Unraveling the Connection

*Emmanuel Ifeanyi Obeagu

Department of Medical Laboratory Science, Kampala International University, Uganda

*Corresponding authour: Emmanuel Ifeanyi Obeagu, Department of Medical Laboratory Science, Kampala International University, Uganda, emmanuelobeagu@yahoo.com, ORCID: 0000-0002-4538-0161

Abstract

Neutrophil chemotaxis plays a pivotal role in directing the migration of neutrophils towards sites of infection or inflammation, ensuring an effective innate immune response. In the context of HIV infection, dysregulation of neutrophil chemotaxis has been implicated in the pathogenesis of gastrointestinal complications, particularly diarrhea. This review article explores the intricate connection between impaired neutrophil chemotaxis and HIV-associated diarrhea, shedding light on the underlying mechanisms and potential therapeutic strategies. HIV-associated diarrhea remains a significant clinical challenge, impacting the quality of life and treatment outcomes of affected individuals despite advances in antiretroviral therapy. Understanding the role of neutrophil chemotaxis in this context provides valuable insights into disease pathogenesis and opportunities for targeted intervention. Dysregulation of these processes can impair neutrophil recruitment to the gut mucosa, compromising host defense mechanisms and exacerbating tissue damage. Altered expression of chemokine receptors, dysregulated signaling pathways, and impaired cytoskeletal rearrangements in neutrophils from HIV-infected individuals contribute to defective chemotactic responses, further exacerbating diarrhea symptoms. Therapeutic implications of targeting impaired neutrophil chemotaxis are explored, with a focus on restoring normal chemotactic responses in neutrophils. Strategies aimed at modulating chemokine receptor signaling, enhancing cytoskeletal dynamics, and restoring gut mucosal immunity may provide opportunities for comprehensive management of diarrhea in HIV-infected individuals. Additionally, assessing neutrophil chemotaxis and associated biomarkers may offer valuable insights into disease severity, progression, and treatment response, guiding personalized management strategies.

Keywords: *Neutrophils, Chemotaxis, HIV, Diarrhea, Gut mucosa, Immune dysregulation, Inflammation, Therapeutic targets, Biomarkers*

Citation: Obeagu EI. Impaired Neutrophil Chemotaxis and HIV-Associated Diarrhea: Unraveling the Connection. Elite Journal of Health Science, 2024; 2(3): 53-67

Introduction

HIV infection remains a global health concern, with gastrointestinal complications such as diarrhea posing significant challenges in management and quality of life for affected individuals. Despite advances in treatment, diarrhea persists as a prevalent and distressing symptom in HIV-infected individuals, underscoring the need for a deeper understanding of its underlying mechanisms. Among the intricate interplay of immune responses in the gut mucosa, neutrophil chemotaxis emerges as a crucial aspect influencing the pathogenesis of diarrhea in HIV-infected individuals. Neutrophil chemotaxis is a finely tuned process essential for directing neutrophils towards sites of infection or tissue damage. Chemokines released by inflamed or infected tissues act as chemoattractants, binding to specific receptors on neutrophils and initiating a cascade of events leading to cell migration. Dysregulation of this process can impair the ability of neutrophils to effectively respond to inflammatory stimuli, compromising host defense mechanisms and exacerbating tissue damage. In the context of HIV infection, dysregulation of neutrophil chemotaxis has been implicated in the pathogenesis of various complications, including gastrointestinal manifestations such as diarrhea. HIV-associated diarrhea remains a significant clinical challenge, affecting a substantial proportion of individuals despite effective antiretroviral therapy. Understanding the role of neutrophil chemotaxis in the context of HIV-associated diarrhea is critical for elucidating its underlying mechanisms and identifying potential therapeutic targets. Several factors contribute to the dysregulation of neutrophil chemotaxis in HIV-infected individuals. Altered expression of chemokine receptors, dysregulated signaling pathways, and impaired cytoskeletal dynamics have been observed in neutrophils from HIV-infected individuals, resulting in defective chemotactic responses. These abnormalities in neutrophil function may compromise the host's ability to control microbial translocation, inflammation, and tissue injury in the gut mucosa, thereby exacerbating diarrhea symptoms.[1-30]

Neutrophil Chemotaxis

Neutrophil chemotaxis is a fundamental process in the innate immune response, crucial for directing the migration of neutrophils towards sites of infection, inflammation, or tissue damage. This dynamic process allows neutrophils, the most abundant white blood cells in circulation, to rapidly respond to tissue injury or invading pathogens, contributing to host defense and tissue repair mechanisms. Chemotaxis is orchestrated by a complex interplay of chemotactic signals, receptor-ligand interactions, and intracellular signaling pathways within neutrophils. At the core of neutrophil chemotaxis are chemotactic signals, such as chemokines and lipid mediators, released by inflamed or infected tissues. These soluble factors serve as chemoattractants, binding to specific receptors on the surface of neutrophils and initiating a series of signaling events that ultimately lead to cell migration. Chemokine receptors, including CXCR1, CXCR2, and fMLP receptors, play a pivotal role in sensing and responding to chemotactic gradients, guiding neutrophils towards the source of inflammation or infection. Upon activation of chemokine receptors, neutrophils undergo cytoskeletal rearrangements, leading to polarization and directional migration towards the chemotactic stimulus. This process involves dynamic changes in the actin cytoskeleton, orchestrated by small GTPases such as Rac and Cdc42, which drive the extension of pseudopods and the formation of a leading edge. Concurrently, integrin activation and adhesion

molecule interactions facilitate the firm adhesion of neutrophils to the endothelium and their subsequent transmigration into tissues. In addition to chemotactic gradients, various factors can modulate neutrophil chemotaxis, including cytokines, microbial products, and cellular interactions. Dysregulation of neutrophil chemotaxis has been implicated in various inflammatory and autoimmune diseases, as well as infectious conditions. Impaired chemotaxis can compromise host defense mechanisms, leading to recurrent infections or chronic inflammation, highlighting the importance of maintaining proper regulation of neutrophil migration.[31-60]

HIV-Associated Diarrhea

HIV-associated diarrhea is a common gastrointestinal complication affecting individuals living with HIV/AIDS, particularly in resource-limited settings and in those with advanced disease stages. It manifests as frequent, watery stools, often accompanied by abdominal cramping, bloating, and weight loss. Despite significant improvements in antiretroviral therapy (ART) and management strategies, diarrhea remains a persistent and distressing symptom, impacting the quality of life and nutritional status of affected individuals. The pathogenesis of HIV-associated diarrhea is multifactorial, involving a complex interplay of viral, microbial, and host factors. Direct viral effects, including HIV-induced enteropathy and enteric viral infections such as cytomegalovirus (CMV) or herpes simplex virus (HSV), contribute to gastrointestinal inflammation and mucosal damage. Furthermore, HIV-associated immune dysfunction, characterized by CD4+ T-cell depletion and chronic immune activation, compromises gut mucosal immunity and barrier function, predisposing individuals to opportunistic infections and microbial translocation. Microbial dysbiosis, marked by alterations in the composition and diversity of gut microbiota, is a hallmark of HIV infection and is implicated in the pathogenesis of diarrhea. Dysregulated immune responses and ART-mediated alterations in gut microbial communities disrupt the delicate balance between commensal and pathogenic bacteria, leading to intestinal dysmotility, malabsorption, and diarrhea. Additionally, co-infections with enteric pathogens such as Cryptosporidium, Giardia, and various bacterial species further exacerbate diarrhea symptoms in HIV-infected individuals.[61-76]

The clinical management of HIV-associated diarrhea involves a comprehensive approach aimed at addressing underlying etiologies, managing symptoms, and optimizing ART regimens. Diagnostic evaluation typically includes stool studies for infectious pathogens, colonoscopy with biopsy for mucosal evaluation, and assessment of ART adherence and tolerance. Treatment strategies may include antimicrobial therapy for identified pathogens, anti-diarrheal agents, probiotics, and dietary modifications to alleviate symptoms and improve nutritional status. Despite these interventions, a subset of HIV-infected individuals may experience persistent or refractory diarrhea, necessitating further investigation and therapeutic interventions. Emerging approaches, such as fecal microbiota transplantation (FMT), microbiome-targeted therapies, and gut mucosal healing agents, hold promise for improving outcomes in individuals with treatment-resistant diarrhea. Furthermore, addressing psychosocial factors, nutritional deficiencies, and medication-related adverse effects is integral to holistic management and improving the overall well-being of individuals living with HIV-associated diarrhea.[77-86]

Impaired Neutrophil Chemotaxis in HIV-Associated Diarrhea

Impaired neutrophil chemotaxis represents a significant aspect of the immune dysregulation observed in HIV infection and may contribute to the pathogenesis of HIV-associated diarrhea. Neutrophils are crucial components of the innate immune system, tasked with responding rapidly to sites of infection or inflammation. Chemotaxis, the directed migration of neutrophils towards chemoattractants released by damaged or infected tissues, is essential for their effective recruitment to sites of mucosal injury in the gastrointestinal tract. In the context of HIV infection, dysregulation of neutrophil chemotaxis has been reported, potentially impacting the ability of neutrophils to migrate efficiently to the gut mucosa in response to inflammatory signals. Altered expression and function of chemokine receptors, such as CXCR1 and CXCR2, have been observed in neutrophils from HIV-infected individuals. Additionally, abnormalities in intracellular signaling pathways involved in chemotaxis, including phosphoinositide 3-kinase (PI3K) and Rho family GTPases, may contribute to defective neutrophil migration. Impaired neutrophil chemotaxis may compromise host defense mechanisms in the gut mucosa, leading to inadequate clearance of microbial pathogens and chronic inflammation. In the setting of HIV-associated diarrhea, this dysregulated immune response may exacerbate mucosal damage and perpetuate gastrointestinal symptoms. Furthermore, the dysbiosis of gut microbiota observed in HIV infection may further disrupt the delicate balance between commensal and pathogenic bacteria, exacerbating intestinal inflammation and diarrhea.[87-90]

Understanding the role of impaired neutrophil chemotaxis in HIV-associated diarrhea is crucial for elucidating its underlying mechanisms and identifying potential therapeutic targets. Targeted interventions aimed at restoring normal chemotactic responses in neutrophils, such as modulating chemokine receptor signaling or enhancing cytoskeletal dynamics, may hold promise for alleviating gut inflammation and improving diarrhea outcomes in HIV-infected individuals. Moreover, assessing neutrophil chemotaxis and associated biomarkers may offer valuable insights into disease severity, progression, and treatment response in HIV-associated diarrhea. Quantifying chemotactic responses in vitro or measuring circulating biomarkers of neutrophil activation and migration could aid in patient stratification, monitoring disease activity, and evaluating therapeutic efficacy.[94-100]

Therapeutic Implications

The recognition of impaired neutrophil chemotaxis in HIV-associated diarrhea presents significant therapeutic implications for managing gastrointestinal complications in HIV-infected individuals. Targeting this dysregulated immune response offers potential avenues for intervention to alleviate symptoms and improve patient outcomes. One therapeutic strategy involves restoring normal neutrophil chemotaxis through the modulation of chemokine receptor signaling pathways. Agents that selectively target chemokine receptors, such as CXCR1 and CXCR2 antagonists or agonists, may help restore the responsiveness of neutrophils to chemoattractants in the gut mucosa. By enhancing the recruitment of neutrophils to sites of inflammation or infection, these agents could bolster host defense mechanisms and mitigate mucosal damage associated with HIV-associated diarrhea. Another approach is to intervene at the level of intracellular signaling pathways involved

in neutrophil chemotaxis. Small molecule inhibitors targeting key signaling molecules, such as phosphoinositide 3-kinase (PI3K) or Rho family GTPases, could potentially restore the cytoskeletal dynamics necessary for efficient neutrophil migration. By modulating these pathways, it may be possible to enhance the directional movement of neutrophils towards inflammatory stimuli in the gut mucosa, thereby reducing tissue damage and inflammation.[101-103]

Furthermore, therapeutic interventions aimed at enhancing gut mucosal immunity and barrier function may complement strategies targeting impaired neutrophil chemotaxis. Agents that promote epithelial repair, such as growth factors or mucosal healing agents, could help restore gut barrier integrity and limit microbial translocation, thereby reducing the inflammatory burden in the gut mucosa. Additionally, therapies aimed at modulating gut microbiota composition, such as probiotics or fecal microbiota transplantation (FMT), may restore microbial homeostasis and alleviate gastrointestinal symptoms in HIV-infected individuals. In addition to pharmacological interventions, lifestyle modifications and supportive care strategies play a crucial role in managing HIV-associated diarrhea. Nutritional supplementation, hydration therapy, and dietary modifications may help alleviate symptoms and improve nutritional status in affected individuals. Moreover, addressing psychosocial factors, medication adherence, and comorbidities is integral to holistic management and improving overall quality of life in HIV-infected individuals with diarrhea.[104-106]

Biomarker Potential

The identification of impaired neutrophil chemotaxis in HIV-associated diarrhea also raises the possibility of utilizing associated biomarkers for diagnostic and prognostic purposes. Biomarkers related to neutrophil function and chemotaxis could offer valuable insights into disease severity, progression, and treatment response in HIV-infected individuals with diarrhea, thereby guiding personalized management strategies. Measurement of circulating biomarkers associated with neutrophil activation and migration may serve as non-invasive diagnostic tools for assessing the severity of gut inflammation and mucosal damage in HIV-associated diarrhea. Elevated levels of these biomarkers, such as neutrophil elastase, myeloperoxidase, or cell-free DNA, could indicate ongoing neutrophil activation and migration to the gut mucosa, reflecting the extent of tissue injury and inflammation. Furthermore, longitudinal studies investigating the dynamics of neutrophil-associated biomarkers could provide valuable prognostic information, allowing for early identification of individuals at increased risk of disease progression or treatment failure. Monitoring changes in circulating biomarkers over time may help predict clinical outcomes, guide treatment decisions, and optimize therapeutic interventions in HIV-infected individuals with diarrhea. In addition to their diagnostic and prognostic utility, neutrophil-associated biomarkers may also have predictive value in identifying individuals at risk of developing complications or comorbidities associated with HIV-associated diarrhea. Elevated levels of circulating biomarkers could potentially serve as early indicators of gut mucosal damage and barrier dysfunction, prompting closer monitoring and preventive interventions to mitigate disease progression and improve long-term outcomes. Moreover, assessing neutrophil-associated biomarkers may offer insights into treatment response and therapeutic efficacy in HIV-associated diarrhea. Changes in

circulating biomarkers following therapeutic interventions could provide valuable information on treatment efficacy and help optimize management strategies for improved clinical outcomes.[106-109]

Conclusion

The identification of impaired neutrophil chemotaxis in HIV-associated diarrhea offers insights into the underlying mechanisms of gastrointestinal complications in HIV-infected individuals. Targeting this dysregulated immune response presents promising therapeutic opportunities for alleviating symptoms and improving patient outcomes. Additionally, the biomarker potential of neutrophil-associated markers provides valuable diagnostic, prognostic, and predictive information, guiding personalized management strategies for individuals with HIV-associated diarrhea. Therapeutic interventions aimed at restoring normal neutrophil function and enhancing gut mucosal immunity hold promise for mitigating inflammation, reducing tissue damage, and alleviating diarrhea severity. Furthermore, longitudinal monitoring of neutrophil-associated biomarkers may offer valuable insights into disease progression, treatment response, and the development of complications.

References

1. Clay PG, Crutchley RD. Noninfectious diarrhea in HIV seropositive individuals: a review of prevalence rates, etiology, and management in the era of combination antiretroviral therapy. Infectious diseases and therapy. 2014; 3:103-122.
2. Pavlinac PB, John-Stewart GC, Naulikha JM, Onchiri FM, Denno DM, Odundo EA, Singa BO, Richardson BA, Walson JL. High-risk enteric pathogens associated with HIV infection and HIV exposure in Kenyan children with acute diarrhoea. Aids. 2014;28(15):2287-2296.
3. Shirley DA, Farr L, Watanabe K, Moonah S. A review of the global burden, new diagnostics, and current therapeutics for amebiasis. InOpen forum infectious diseases 2018 Jul (Vol. 5, No. 7, p. ofy161). US: Oxford University Press.
4. Obiako OR, Muktar HM. Challenges if HIV treatment in resource-poor countries: a review. Nigerian journal of medicine. 2010;19(4):361-368.
5. Watermeyer G, Katsidzira L, Setshedi M, Devani S, Mudombi W, Kassianides C. Inflammatory bowel disease in sub-Saharan Africa: epidemiology, risk factors, and challenges in diagnosis. The Lancet Gastroenterology & Hepatology. 2022;7(10):952-961.
6. Obeagu EI, Okwuanaso CB, Edoho SH, Obeagu GU. Under-nutrition among HIV-exposed Uninfected Children: A Review of African Perspective. Madonna University journal of Medicine and Health Sciences. 2022;2(3):120-127.
7. Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. Madonna University journal of Medicine and Health Sciences. 2023 ;3(1):7-12. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/91.
8. Obeagu EI, Obeagu GU. An update on premalignant cervical lesions and cervical cancer screening services among HIV positive women. J Pub Health Nutri. 2023; 6 (2). 2023;

141:1-2. links/63e538ed64252375639dd0df/An-update-on-premalignant-cervical-lesions-and-cervical-cancer-screening-services-among-HIV-positive-women.pdf.

9. Ezeoru VC, Enweani IB, Ochiabuto O, Nwachukwu AC, Ogbonna US, Obeagu EI. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. Journal of Pharmaceutical Research International. 2021;33(4):10-19.
10. Omo-Emmanuel UK, Chinedum OK, Obeagu EI. Evaluation of laboratory logistics management information system in HIV/AIDS comprehensive health facilities in Bayelsa State, Nigeria. Int J Curr Res Med Sci. 2017;3(1): 21-38.DOI: 10.22192/ijcrms.2017.03.01.004
11. Obeagu EI, Obeagu GU, Musiimenta E, Bot YS, Hassan AO. Factors contributing to low utilization of HIV counseling and testing services. Int. J. Curr. Res. Med. Sci. 2023;9(2): 1-5.DOI: 10.22192/ijcrms.2023.09.02.001
12. Obeagu EI, Obeagu GU. An update on survival of people living with HIV in Nigeria. J Pub Health Nutri. 2022; 5 (6). 2022;129. links/645b4bfcf3512f1cc5885784/An-update-on-survival-of-people-living-with-HIV-in-Nigeria.pdf.
13. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, Dike PN, Oguh DN. Facilitators and barriers to retention in HIV care among HIV infected MSM attending Community Health Center Yaba, Lagos Nigeria. Journal of Pharmaceutical Research International. 2021;33(52B):10-19.
14. Obeagu EI, Ogbonna US, Nwachukwu AC, Ochiabuto O, Enweani IB, Ezeoru VC. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. Journal of Pharmaceutical Research International. 2021;33(4):10-19.
15. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng UE, Ikpeme M, Bassey JO, Paul AO. TB Infection Control in TB/HIV Settings in Cross River State, Nigeria: Policy Vs Practice. Journal of Pharmaceutical Research International. 2020;32(22):101-119.
16. Obeagu EI, Eze VU, Alaeboh EA, Ochei KC. Determination of haematocrit level and iron profile study among persons living with HIV in Umuahia, Abia State, Nigeria. J BioInnovation. 2016; 5:464-471. links/592bb4990f7e9b9979a975cf/DETERMINATION-OF-HAEMATOCRIT-LEVEL-AND-IRON-PROFILE-STUDY-AMONG-PERSONS-LIVING-WITH-HIV-IN-UMUAHIA-ABIA-STATE-NIGERIA.pdf.
17. Ifeanyi OE, Obeagu GU. The values of prothrombin time among HIV positive patients in FMC owerri. International Journal of Current Microbiology and Applied Sciences. 2015;4(4):911-916. https://www.academia.edu/download/38320140/Obeagu_Emmanuel_Ifeanyi_and_Obeagu__Getrude_Uzoma2.EMMA1.pdf.
18. Izuchukwu IF, Ozims SJ, Agu GC, Obeagu EI, Onu I, Amah H, Nwosu DC, Nwanjo HU, Edward A, Arunsi MO. Knowledge of preventive measures and management of HIV/AIDS victims among parents in Umuna Orlu community of Imo state Nigeria. Int. J. Adv. Res. Biol. Sci. 2016;3(10): 55-65.DOI; 10.22192/ijarbs.2016.03.10.009
19. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV and TB co-infection among patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. IOSR J Pharm Biol Sci. 2017;12(4):70-75. links/5988ab6d0f7e9b6c8539f73d/HIV-and-TB-co-infection-among-patients-who-used-Directly-Observed-Treatment-Short-course-centres-in-Yenagoa-Nigeria.pdf

20. Oloro OH, Oke TO, Obeagu EI. Evaluation of Coagulation Profile Patients with Pulmonary Tuberculosis and Human Immunodeficiency Virus in Owo, Ondo State, Nigeria. Madonna University journal of Medicine and Health Sciences. 2022;2(3):110-119.
21. Nwosu DC, Obeagu EI, Nkwocha BC, Nwanna CA, Nwanjo HU, Amadike JN, Elendu HN, Ofoedeme CN, Ozims SJ, Nwankpa P. Change in Lipid Peroxidation Marker (MDA) and Non enzymatic Antioxidants (VIT C & E) in HIV Seropositive Children in an Urban Community of Abia State. Nigeria. J. Bio. Innov. 2016;5(1):24-30. links/5ae735e9a6fdcc5b33eb8d6a/CHANGE-IN-LIPID-PEROXIDATION-MARKER-MDAAND-NON-ENZYMATIC-ANTIOXIDANTS-VIT-C-E-IN-HIV-SEROPOSITIVE-CHILDREN-IN-AN-URBAN-COMMUNITY-OF-ABIA-STATE-NIGERIA.pdf.
22. Igwe CM, Obeagu IE, Ogbuabor OA. Clinical characteristics of people living with HIV/AIDS on ART in 2014 at tertiary health institutions in Enugu, Nigeria. J Pub Health Nutri. 2022; 5 (6). 2022;130. links/645a166f5762c95ac3817d32/Clinical-characteristics-of-people-living-with-HIV-AIDS-on-ART-in-2014-at-tertiary-health-institutions-in-Enugu.pdf.
23. Ifeanyi OE, Obeagu GU, Ijeoma FO, Chioma UI. The values of activated partial thromboplastin time (APTT) among HIV positive patients in FMC Owerri. Int J Curr Res Aca Rev. 2015; 3:139-144. https://www.academia.edu/download/38320159/Obeagu_Emmanuel_Ifeanyi3__et_al.IJCRAR.pdf.
24. Obiomah CF, Obeagu EI, Ochei KC, Swem CA, Amachukwu BO. Hematological indices o HIV seropositive subjects in Nnamdi Azikiwe University teaching hospital (NAUTH), Nnewi. Ann Clin Lab Res. 2018;6(1):1-4. links/5aa2bb17a6fdccd544b7526e/Haematological-Indices-of-HIV-Seropositive-Subjects-at-Nnamdi-Azikiwe.pdf
25. Omo-Emmanuel UK, Ochei KC, Osuala EO, Obeagu EI, Onwuasoanya UF. Impact of prevention of mother to child transmission (PMTCT) of HIV on positivity rate in Kafanchan, Nigeria. Int. J. Curr. Res. Med. Sci. 2017;3(2): 28-34.DOI: 10.22192/ijcrms.2017.03.02.005
26. Esimai BN, Obeagu EI. Prevalence of Isolated Agent in Diarrheal Infections of Children O-3 Years in Anambra State in Relation to Sex: A Survey of Five Rural Communities. J Biomed Sci. 2022;11(8):73. links/630c87eb1ddd447021194fca/Prevalence-of-Isolated-Agent-in-Diarrheal-Infections-of-Children-O-3-Years-in-Anambra-State-in-Relation-to-Sex-A-Survey-of-Five-Rural-Communities.pdf.
27. Ezimah UA, Obeagu EI, Ezimah CO, Ezimah A, Nto NJ. Diarrhoeal diseases of acquired immunodeficiency syndrome stimulate more depletion of total antioxidant status. Int. J. Adv. Multidiscip. Res. 2016;3(4):23-5. links/592bb593aca27295a80b964c/International-Journal-of-Advanced-Multidisciplinary-Research-IJAMR-Diarrhoeal-diseases-of-acquired-immunodeficiency-syndrome-stimulate-more-depletion-of-total-antioxidant-status.pdf.
28. Ojo BO, Abdulrahman OA, Haassan AO, Obeagu EI, Olamijuwon PB, Oyeromi BO, Oluwanisola DO, Kelvin U. Plasmid Profiling of Bacteria Associated with Gastroenteritis

among Children in Owo, Ondo State. Asian Journal of Research and Reports in Gastroenterology. 2022 Jul 26;6(2):29-41.
29. Obeagu GU, Obeagu EI. Diarrhoea disease: A dangerous childhood disease. CPQ Women Child Health. 2019;1(6):01-8.
30. Ogbu IS, Okafor EO, Obeagu EI, Ogbu CC, Esimai BN, Okeke NJ, Ukeekwe CO. Effect of Oral Administration of the Leaf Extract of Uvaria chamae (Mmimi Ohia) in Albino Wistar Rats. Journal of Pharmaceutical Research International. 2020 Oct 6;32(24):52-6.
31. Obeagu EI, Obeagu GU, Habimana JB. Iron Deficiency Anaemia in Children. International Research in Medical and Health Sciences. 2023 Sep 11;6(4):26-32.
32. Aizaz M, Abbas FA, Abbas A, Tabassum S, Obeagu EI. Alarming rise in HIV cases in Pakistan: Challenges and future recommendations at hand. Health Science Reports. 2023;6(8):e1450.
33. Obeagu EI, Amekpor F, Scott GY. An update of human immunodeficiency virus infection: Bleeding disorders. J Pub Health Nutri. 2023; 6 (1). 2023;139. links/645b4a6c2edb8e5f094d9bd9/An-update-of-human-immunodeficiency-virus-infection-Bleeding.pdf.
34. Obeagu EI, Scott GY, Amekpor F, Ofodile AC, Edoho SH, Ahamefula C. Prevention of New Cases of Human Immunodeficiency Virus: Pragmatic Approaches of Saving Life in Developing Countries. Madonna University journal of Medicine and Health Sciences. 2022;2(3):128-134. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/86.
35. Walter O, Anaebo QB, Obeagu EI, Okoroiwu IL. Evaluation of Activated Partial Thromboplastin Time and Prothrombin Time in HIV and TB Patients in Owerri Metropolis. Journal of Pharmaceutical Research International. 2022:29-34.
36. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng EU, Ikpeme M, Bassey JO, Paul AO. Cascade variabilities in TB case finding among people living with HIV and the use of IPT: assessment in three levels of care in cross River State, Nigeria. Journal of Pharmaceutical Research International. 2020;32(24):9-18.
37. Jakheng SP, Obeagu EI. Seroprevalence of human immunodeficiency virus based on demographic and risk factors among pregnant women attending clinics in Zaria Metropolis, Nigeria. J Pub Health Nutri. 2022; 5 (8). 2022;137. links/6317a6b1acd814437f0ad268/Seroprevalence-of-human-immunodeficiency-virus-based-on-demographic-and-risk-factors-among-pregnant-women-attending-clinics-in-Zaria-Metropolis-Nigeria.pdf.
38. Obeagu EI, Obeagu GU. A Review of knowledge, attitudes and socio-demographic factors associated with non-adherence to antiretroviral therapy among people living with HIV/AIDS. Int. J. Adv. Res. Biol. Sci. 2023;10(9):135-142.DOI: 10.22192/ijarbs.2023.10.09.015 links/6516faa61e2386049de5e828/A-Review-of-knowledge-attitudes-and-socio-demographic-factors-associated-with-non-adherence-to-antiretroviral-therapy-among-people-living-with-HIV-AIDS.pdf
39. Obeagu EI, Onuoha EC. Tuberculosis among HIV Patients: A review of Prevalence and Associated Factors. Int. J. Adv. Res. Biol. Sci. 2023;10(9):128-134.DOI: 10.22192/ijarbs.2023.10.09.014 links/6516f938b0df2f20a2f8b0e0/Tuberculosis-among-HIV-Patients-A-review-of-Prevalence-and-Associated-Factors.pdf.

40. Obeagu EI, Ibeh NC, Nwobodo HA, Ochei KC, Iwegbulam CP. Haematological indices of malaria patients coinfected with HIV in Umuahia. Int. J. Curr. Res. Med. Sci. 2017;3(5):100-104.DOI: 10.22192/ijcrms.2017.03.05.014 https://www.academia.edu/download/54317126/Haematological_indices_of_malaria_patients_coinfected_with_HIV.pdf
41. Jakheng SP, Obeagu EI, Abdullahi IO, Jakheng EW, Chukwueze CM, Eze GC, Essien UC, Madekwe CC, Madekwe CC, Vidya S, Kumar S. Distribution Rate of Chlamydial Infection According to Demographic Factors among Pregnant Women Attending Clinics in Zaria Metropolis, Kaduna State, Nigeria. South Asian Journal of Research in Microbiology. 2022;13(2):26-31.
42. Ifeanyi OE, Chibunna OM, Braxton NA, Uche EC. Impact of Plasmodium falciparum malaria and hookworm infection on anaemia among pregnant women of ikwuano local government area, Abia state, Nigeria. Int J Curr Microbiol Appl Sci. 2014;3(1):104-1.
43. Ifeanyi OE. A review on free radicals and antioxidants. Int. J. Curr. Res. Med. Sci. 2018;4(2):123-33.DOI: 10.22192/ijcrms.2018.04.02.019
44. Nwandkor UU, Ifeanyi OE. Bacteriological assessment of different borehole drinking water sources in Umuahia Metropolis. International Journal of Current Microbiology and Applied Sciences. 2015;4(5):1139-50. links/5712132008ae39beb87a2ee4/Bacteriological-Assessment-of-Different-Borehole-Drinking-Water-Sources-in-Umuahia-Metropolis.pdf.
45. Stella EI, Ifeanyi OE. A review on salmonella species and indicator organisms in drinking water. Int J Compr Res Biol Sci. 2018;5(2):5-23. *DOI: http://dx.doi.org/10.22192/ijcrbs.2018.05.02.002*
46. Ugwuzor NU, Ifeanyi OE, Onyenweaku FC. Bacteriolcgical Assessment of Stream Drinking Water from various Sources in Umuahia Metropolis. World Journal of Pharmaceutical Research. 2015 Mar 19;4(6):122-37.
47. Yang H, Biermann MH, Brauner JM, Liu Y, Zhao Y, Herrmann M. New insights into neutrophil extracellular traps: mechanisms of formation and role in inflammation. Frontiers in immunology. 2016; 7:207281.
48. Okorie HM, Obeagu Emmanuel I, Okpoli Henry CH, Chukwu Stella N. Comparative study of enzyme linked immunosorbent assay (Elisa) and rapid test screening methods on HIV, Hbsag, Hcv and Syphilis among voluntary donors in. Owerri, Nigeria. J Clin Commun Med. 2020;2(3):180-183.DOI: **DOI:** 10.32474/JCCM.2020.02.000137 links/5f344530458515b7291bd95f/Comparative-Study-of-Enzyme-Linked-Immunosorbent-Assay-ElISA-and-Rapid-Test-Screening-Methods-on-HIV-HBsAg-HCV-and-Syphilis-among-Voluntary-Donors-in-Owerri-Nigeria.pdf.
49. Ezugwu UM, Onyenekwe CC, Ukibe NR, Ahaneku JE, Onah CE, Obeagu EI, Emeje PI, Awalu JC, Igbokwe GE. Use of ATP, GTP, ADP and AMP as an Index of Energy Utilization and Storage in HIV Infected Individuals at NAUTH, Nigeria: A Longitudinal, Prospective, Case-Controlled Study. Journal of Pharmaceutical Research International. 2021;33(47A):78-84.
50. Emannuel G, Martin O, Peter OS, Obeagu EI, Daniel K. Factors Influencing Early Neonatal Adverse Outcomes among Women with HIV with Post Dated Pregnancies Delivering at Kampala International University Teaching Hospital, Uganda. Asian Journal

of Pregnancy and Childbirth. 2023 Jul 29;6(1):203-211. http://research.sdpublishers.net/id/eprint/2819/.

51. Igwe MC, Obeagu EI, Ogbuabor AO, Eze GC, Ikpenwa JN, Eze-Steven PE. Socio-Demographic Variables of People Living with HIV/AIDS Initiated on ART in 2014 at Tertiary Health Institution in Enugu State. Asian Journal of Research in Infectious Diseases. 2022;10(4):1-7.
52. Vincent CC, Obeagu EI, Agu IS, Ukeagu NC, Onyekachi-Chigbu AC. Adherence to Antiretroviral Therapy among HIV/AIDS in Federal Medical Centre, Owerri. Journal of Pharmaceutical Research International. 2021;33(57A):360-368.
53. Igwe MC, Obeagu EI, Ogbuabor AO. Analysis of the Factors and Predictors of Adherence to Healthcare of People Living With Hiv/Aids In Tertiary Health Institutions In Enugu State. Madonna University Journal of Medicine and Health Sciences. 2022;2(3):42-57. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/75.
54. Madekwe CC, Madekwe CC, Obeagu EI. Inequality of monitoring in Human Immunodeficiency Virus, Tuberculosis and Malaria: A Review. Madonna University journal of Medicine and Health Sciences. 2022;2(3):6-15. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/69
55. Echendu GE, Vincent CC, Ibebuike J, Asodike M, Naze N, Chinedu EP, Ohale B, Obeagu EI. WEIGHTS OF INFANTS BORN TO HIV INFECTED MOTHERS: A PROSPECTIVE COHORT STUDY IN FEDERAL MEDICAL CENTRE, OWERRI, IMO STATE. European Journal of Pharmaceutical and Medical Research, 2023; 10(8): 564-568
56. Nwosu DC, Nwanjo HU, Okolie NJ, Ikeh K, Ajero CM, Dike J, Ojiegbe GC, Oze GO, Obeagu EI, Nnatunanya I, Azuonwu O. BIOCHEMICAL ALTERATIONS IN ADULT HIV PATIENTS ON ANTIRETRQVIRAL THERAPY. World Journal of Pharmacy and Pharmaceutical Sciences, 2015; 4(3): 153-160**.** links/5a4fd0500f7e9bbc10526b38/BIOCHEMICAL-ALTERATIONS-IN-ADULT-HIV-PATIENTS-ON-ANTIRETRQVIRAL-THERAPY.pdf.
57. Obeagu EI, Obeagu GU. Effect of CD4 Counts on Coagulation Parameters among HIV Positive Patients in Federal Medical Centre, Owerri, Nigeria. Int. J. Curr. Res. Biosci. Plant Biol. 2015;2(4):45-49.
58. Obeagu EI, Nwosu DC. Adverse drug reactions in HIV/AIDS patients on highly active antiretro viral therapy: a review of prevalence. Int. J. Curr. Res. Chem. Pharm. Sci. 2019;6(12):45-8.DOI: 10.22192/ijcrcps.2019.06.12.004 links/650aba1582f01628f0335795/Adverse-drug-reactions-in-HIV-AIDS-patients-on-highly-active-antiretro-viral-therapy-a-review-of-prevalence.pdf.
59. Obeagu EI, Scott GY, Amekpor F, Obeagu GU. Implications of CD4/CD8 ratios in Human Immunodeficiency Virus infections. Int. J. Curr. Res. Med. Sci. 2023;9(2):6-13.DOI: 10.22192/ijcrms.2023.09.02.002 links/645a4a462edb8e5f094ad37c/Implications-of-CD4-CD8-ratios-in-Human-Immunodeficiency-Virus-infections.pdf.
60. Obeagu EI, Ochei KC, Okeke EI, Anode AC. Assessment of the level of haemoglobin and erythropoietin in persons living with HIV in Umuahia. Int. J. Curr. Res. Med. Sci. 2016;2(4):29-33. links/5711c47508aeebe07c02496b/Assessment-of-the-level-of-haemoglobin-and-erythropoietin-in-persons-living-with-HIV-in-Umuahia.pdf.

61. Ifeanyi OE, Obeagu GU. The Values of CD4 Count, among HIV Positive Patients in FMC Owerri. Int. J. Curr. Microbiol. App. Sci. 2015;4(4):906-910. https://www.academia.edu/download/38320134/Obeagu_Emmanuel_Ifeanyi_and_Obeagu__Getrude_Uzoma.EMMA2.pdf.
62. Obeagu EI, Okeke EI, Anonde Andrew C. Evaluation of haemoglobin and iron profile study among persons living with HIV in Umuahia, Abia state, Nigeria. Int. J. Curr. Res. Biol. Med. 2016;1(2):1-5.
63. Ibebuike JE, Nwokike GI, Nwosu DC, Obeagu EI. A Retrospective Study on Human Immune Deficiency Virus among Pregnant Women Attending Antenatal Clinic in Imo State University Teaching Hospital. *International Journal of Medical Science and Dental Research,* 2018; 1 (2):08-14. https://www.ijmsdr.org/published%20paper/li1i2/A%20Retrospective%20Study%20on%20Human%20Immune%20Deficiency%20Virus%20among%20Pregnant%20Women%20Attending%20Antenatal%20Clinic%20in%20Imo%20State%20University%20Teaching%20Hospital.pdf.
64. Obeagu EI, Obarezi TN, Omeh YN, Okoro NK, Eze OB. Assessment of some haematological and biochemical parametrs in HIV patients before receiving treatment in Aba, Abia State, Nigeria. Res J Pharma Biol Chem Sci. 2014; 5:825-830.
65. Obeagu EI, Obarezi TN, Ogbuabor BN, Anaebo QB, Eze GC. Pattern of total white blood cell and differential count values in HIV positive patients receiving treatment in Federal Teaching Hospital Abakaliki, Ebonyi State, Nigeria. International Journal of Life Science, Biotechnology and Pharama Research. 2014; 391:186-189.
66. Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. Madonna University journal of Medicine and Health Sciences. 2023; 3 (1): 7-12.
67. Oloro OH, Obeagu EI. A Systematic Review on Some Coagulation Profile in HIV Infection. International Journal of Innovative and Applied Research. 2022;10(5):1-11.
68. Nwosu DC, Obeagu EI, Nkwuocha BC, Nwanna CA, Nwanjo HU, Amadike JN, Ezemma MC, Okpomeshine EA, Ozims SJ, Agu GC. Alterations in superoxide dismutiase, vitamins C and E in HIV infected children in Umuahia, Abia state. International Journal of Advanced Research in Biological Sciences. 2015;2(11):268-271.
69. Ifeanyi OE, Uzoma OG, Stella EI, Chinedum OK, Abum SC. Vitamin D and insulin resistance in HIV sero positive individuals in Umudike. Int. J. Curr. Res. Med. Sci. 2018;4(2):104-108.
70. Ifeanyi OE, Leticia OI, Nwosu D, Chinedum OK. A Review on blood borne viral infections: universal precautions. Int. J. Adv. Res. Biol. Sci. 2018;5(6):60-66.
71. Nwovu AI, Ifeanyi OE, Uzoma OG, Nwebonyi NS. Occurrence of Some Blood Borne Viral Infection and Adherence to Universal Precautions among Laboratory Staff in Federal Teaching Hospital Abakaliki Ebonyi State. Arch Blood Transfus Disord. 2018;1(2).
72. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV and TB co-infection among patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. IOSR J Pharm Biol Sci. 2017;12(4):70-75.
73. Obeagu EI. Effects of Long-Term Omeprazole Use on Red Blood Cells: A Review. Elite Journal of Medica Science. 2024;2(1):44-52.

74. Onyeaghala EO, Maxwel EA, Obeagu EI, Hassan AO. Assessment of the Problems Associated with the use of Public Latrine System in Ife-North Local Government, Osun State, Nigeria. RESEARCH IN MEDICAL SCIENCES (NIJRMS). 2024;5(1).
75. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, Dike PN, Oguh DN. Facilitators and barriers to retention in HIV care among HIV infected MSM attending Community Health Center Yaba, Lagos Nigeria. Journal of Pharmaceutical Research International. 2021;33(52B):10-19.
76. Obeagu EI, Obeagu GU, Ede MO, Odo EO, Buhari HA. Translation of HIV/AIDS knowledge into behavior change among secondary school adolescents in Uganda: A review. Medicine (Baltimore). 2023;102(49): e36599. doi: 10.1097/MD.0000000000036599. PMID: 38065920; PMCID: PMC10713174.
77. Anyiam AF, Arinze-Anyiam OC, Irondi EA, Obeagu EI. Distribution of ABO and rhesus blood grouping with HIV infection among blood donors in Ekiti State Nigeria. Medicine (Baltimore). 2023;102(47): e36342. doi: 10.1097/MD.0000000000036342. PMID: 38013335; PMCID: PMC10681551.
78. Echefu SN, Udosen JE, Akwiwu EC, Akpotuzor JO, Obeagu EI. Effect of Dolutegravir regimen against other regimens on some hematological parameters, CD4 count and viral load of people living with HIV infection in South Eastern Nigeria. Medicine (Baltimore). 2023;102(47): e35910. doi: 10.1097/MD.0000000000035910. PMID: 38013350; PMCID: PMC10681510.
79. Opeyemi AA, Obeagu EI. Regulations of malaria in children with human immunodeficiency virus infection: A review. Medicine (Baltimore). 2023;102(46): e36166. doi: 10.1097/MD.0000000000036166. PMID: 37986340; PMCID: PMC10659731.
80. Obeagu EI, Obeagu GU, Obiezu J, Ezeonwumelu C, Ogunnaya FU, Ngwoke AO, Emeka-Obi OR,
81. Obeagu EI, Ubosi NI, Uzoma G. Storms and Struggles: Managing HIV Amid Natural Disasters. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(11):14-25.
82. Obeagu EI, Obeagu GU. Human Immunodeficiency Virus and tuberculosis infection: A review of prevalence of associated factors. Int. J. Adv. Multidiscip. Res. 2023;10(10):56-62.
83. Obeagu EI, Malot S, Obeagu GU, Ugwu OP. HIV resistance in patients with Sickle Cell Anaemia. Newport International Journal of Scientific and Experimental Sciences (NIJSES). 2023;3(2):56-9.
84. Obeagu EI, Obeagu GU. Unmasking the Truth: Addressing Stigma in the Fight Against HIV. Elite Journal of Public Health. 2024;2(1):8-22.
85. Obeagu EI, Obeagu GU, Okwuanaso CB. Optimizing Immune Health in HIV Patients through Nutrition: A Review. Elite Journal of Immunology. 2024;2(1):14-33.
86. Obeagu EI, Obeagu GU. Utilization of immunological ratios in HIV: Implications for monitoring and therapeutic strategies. Medicine. 2024;103(9): e37354.
87. Obeagu EI, Obeagu GU. CD8 Dynamics in HIV Infection: A Synoptic Review. Elite Journal of Immunology. 2024;2(1):1-3.
88. Obeagu EI, Obeagu GU. Implications of B Lymphocyte Dysfunction in HIV/AIDS. Elite Journal of Immunology. 2024;2(1):34-46.

89. Obeagu EI, Obeagu GU. Maternal Influence on Infant Immunological Responses to HIV: A Review. Elite Journal of Laboratory Medicine. 2024;2(1):46-58.
90. Obeagu EI, Obeagu GU. Understanding B Lymphocyte Functions in HIV Infection: Implications for Immune Dysfunction and Therapeutic Strategies. Elite Journal of Medicine. 2024;2(1):35-46.
91. Obeagu EI, Obeagu GU. Platelet-Driven Modulation of HIV: Unraveling Interactions and Implications. Journal home page: http://www. journalijiar. com.;12(01).
92. Obeagu EI, Anyiam AF, Obeagu GU. Managing Hematological Complications in HIV: Erythropoietin Considerations. Elite Journal of HIV. 2024;2(1):65-78.
93. Obeagu EI, Obeagu GU, Hauwa BA, Umar AI. Hematocrit Variations in HIV Patients Co-infected with Malaria: A Comprehensive Review. Journal home page: http://www. journalijiar. com.;12(01).
94. ObeaguEI AA, Obeagu GU. Synergistic Effects of Blood Transfusion and HIV in Children Under 5 Years with Severe Malaria: A Review. Elite Journal of HIV. 2024;2(1):31-50.
95. Obeagu EI, Anyiam AF, Obeagu GU. Unveiling B Cell Mediated Immunity in HIV Infection: Insights, Challenges, and Potential Therapeutic Avenues. Elite Journal of HIV. 2024;2(1):1-5.
96. Obeagu EI, Obeagu GU. Hematocrit Fluctuations in HIV Patients Co-infected with Malaria Parasites: A Comprehensive Review. Int. J. Curr. Res. Med. Sci. 2024;10(1):25-36.
97. Cheah IK, Halliwell B. Could ergothioneine aid in the treatment of coronavirus patients? Antioxidants. 2020;9(7):595.
98. Obeagu EI, Obeagu GU. Transfusion Therapy in HIV: Risk Mitigation and Benefits for Improved Patient Outcomes. Sciences. 2024;4(1):32-7.
99. Obeagu EI, Obeagu GU. Mental Health and Psychosocial Effects of natural disaster on HIV Patients. Sciences. 2024;4(1):38-44.
100. Obeagu EI, Obeagu GU. Eosinophil-Associated Changes in Neonatal Thymic T Regulatory Cell Populations in HIV-Infected Pregnancies. Elite Journal of Health Science. 2024;2(1):33-42.
101. Obeagu EI, Obeagu GU. Advances in Understanding the Impact of Blood Transfusion on Anemia Resolution in HIV-Positive Children with Severe Malaria: A Comprehensive Review. Elite Journal of Haematology. 2024;2(1):26-41.
102. Obeagu EI, Ayogu EE, Obeagu GU. Interactions between Blood Transfusion and Antiretroviral Medications: Implications for Patient Care. Elite Journal of Medicine. 2024;2(2):104-15.
103. Obeagu EI, Obeagu GU. Maternal Eosinophilic Responses in HIV-Positive Pregnant Women: Unraveling Immunological Dynamics for Improved Maternal-Fetal Health. Elite Journal of Immunology. 2024;2(1):47-64.
104. Obeagu EI, Anyanwu CN, Obeagu GU. Challenges and Considerations in Managing Blood Transfusion for Individuals with HIV. Elite Journal of HIV. 2024;2(2):1-7.
105. Obeagu EI, Ubosi NI, Obeagu GU, Akram M. Early Infant Diagnosis: Key to Breaking the Chain of HIV Transmission. Elite Journal of Public Health. 2024;2(1):52-61.
106. Obeagu EI, Obeagu GU. Understanding Hematocrit Fluctuations in HIV-Malaria Coinfection for Improved Management. Elite Journal of Public Health. 2024;2(1):22-34.

107. Obeagu EI, Obeagu GU. The Impact of Erythropoietin on Preeclampsia in HIV-Positive Women: A Review. Elite Journal of Nursing and Health Science. 2024;2(1):21-31.
108. Obeagu EI, Obeagu GU. Platelet Distribution Width (PDW) as a Prognostic Marker for Anemia Severity in HIV Patients: A Comprehensive Review. Journal home page: http://www. journalijiar. com.;12(01).
109. Serrano-Villar S, Talavera-Rodríguez A, Gosalbes MJ, Madrid N, Pérez-Molina JA, Elliott RJ, Navia B, Lanza VF, Vallejo A, Osman M, Dronda F. Fecal microbiota transplantation in HIV: A pilot placebo-controlled study. Nature Communications. 2021;12(1):1139.